Results 161 to 170 of about 41,111 (239)

Polymyxin B lethality requires energy-dependent outer membrane disruption. [PDF]

Nat Microbiol
Borrelli C, Douglas EJA, Riley SMA, Lemonidi AE, Larrouy-Maumus G, Lu WJ, Bonev BB, Edwards AM, Hoogenboom BW.   +8 more
europepmc   +1 more source

Polymyxin B or polymyxin E: does it really matter? [PDF]

Journal of Pharmacy Practice and Research, 2018
openaire   +1 more source

Comparative study on the wound healing effects of local versus systemic application of Polymyxin B in mice infected with multidrug-resistant <i>Pseudomonas aeruginosa</i>. [PDF]

Front Microbiol
Ma C, Wang D, Zhang B, Xu J, Lin M, Zheng Y, Guo Y.   +6 more
europepmc   +1 more source

Synthesis and long-term antibacterial performance of nano-montmorillonite-loaded polymyxin B (NMMT@PMB) against Salmonella in an ex vivo study. [PDF]

Sci Rep
Han Y, Yang X, Jia Y, Liu M, Sun X, Yu D, Zhang D.   +6 more
europepmc   +1 more source

Case Report: Polymyxin B-induced anaphylactic shock. [PDF]

Front Pharmacol
Liu W, Gao B, Xie S, Yin Y.
europepmc   +1 more source

A rare drug reaction: Toxic epidermal necrolysis following polymyxin B administration in a post-Bentall procedure.

Indian J Pharmacol
Patel BB, Patel RB, Hajariwala NR, Maheshwari P, Ganju A, Trivedi C.   +5 more
europepmc   +1 more source

Polymyxin B Induced Acute Diaphragmatic Paralysis: A Case Report Based on Therapeutic Drug Monitoring. [PDF]

Pharmacol Res Perspect
Zhang Y, Tang X, Li Y, Su X, Zhong X, Huang Z.   +5 more
europepmc   +1 more source

Combination Therapy of Cefiderocol and Polymyxin B Against Pseudomonas aeruginosa Keratitis Isolates In Vitro. [PDF]

Transl Vis Sci Technol
Romanowski EG, Young EK, Mumper SM, Yates KA, Wozniak RAF, Zegans ME, Shanks RMQ.   +6 more
europepmc   +1 more source

Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: a real-world cohort study. [PDF]

J Pharm Policy Pract
Zhang W, Chen C, Li D, Zhou Z, Sheng B, Hu Y, Zhang Z.   +6 more
europepmc   +1 more source

Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens. [PDF]

RSC Med Chem
Na TU, Hermant YO, Siow A, Owen JG, Chan STS, Painter GF, Hanna CC, Daysh Z, Goggin BL, Allison JR, Sander V, Davidson AJ, Campbell G, Ferguson SA, Cook GM, Harris PWR, Brimble MA, Cameron AJ.   +17 more
europepmc   +1 more source